Vical, Inc. has restructured to conserve capital. The company will eliminate 47 positions, or approximately 39% of its total workforce, after which, it will have approximately 74 employees. The company is also focusing its resources on its infectious disease vaccine programs and terminating activities related to Allovectin, its investigational cancer immunotherapy, which recently failed to meet Phase III efficacy endpoints. The company expects to incur restructuring charges of approximately $2.2...